Emergent BioSolutions | EBS - تكلفة المبيعات





تكلفة المبيعات تغيير تاريخ
Acadia Pharmaceuticals USD 24.79M 1.43M 2026-03
Akebia Therapeutics USD 10.34M 441K 2025-12
ALKERMES USD 120.7M 47.44M 2026-06
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amarin USD 26.05M 1.41M 2025-12
ANI Pharmaceuticals USD 114.5M 8.38M 2026-03
BioMarin Pharmaceutical USD 199.48M 37.93M 2026-03
Coherus Biosciences USD 4.04M 324K 2025-12
Emergent BioSolutions USD 381.2M 226.1M 2023-06
Exelixis USD 19.95M 6.53M 2026-03
Glaxosmithkline GBP 1.88B 1.6B 2026-03
Heron Therapeutics USD 11.12M 795K 2025-12
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Ironwood Pharmaceuticals USD 29.83M 560K 2024-09
Lexicon Pharmaceuticals USD 201K 191K 2025-12
Lonza CHF 2.28B 189M 2025-06
Merck USD 2.94B 380M 2026-03
Moderna USD 93M 862M 2026-06
Myriad Genetics USD 63M 1.1M 2025-12
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pacira USD 50.74M 3.89M 2026-03
Pfizer USD 4.59B 1.7B 2026-03
PTC Therapeutics USD 39.61M 23.31M 2026-03
Sanofi EUR 3.02B 656M 2026-06
Sarepta Therapeutics USD 109.46M 289.93M 2026-03
United Therapeutics USD 133.4M 341.3M 2026-03
Vanda Pharmaceuticals USD 198.77M 151.12M 2024-12